Dr. Scheffer C.G. Tseng is a world-renowned ophthalmic surgeon and pioneer in ocular surface reconstruction whose innovative work has transformed regenerative medicine. As co-founder and Chief Scientific Officer of BioTissue, he leads the development of cutting-edge therapies using human birth tissues for regenerative healing applications. Dr. Tseng earned his medical degree from National Taiwan University and completed a Doctorate in Experimental Pathology from the University of California, establishing a strong foundation in both clinical practice and scientific research. His rigorous training continued with an ophthalmology residency at the prestigious Wilmer Eye Institute at Johns Hopkins and a fellowship in cornea and external diseases at Massachusetts Eye and Ear Infirmary. Prior to co-founding BioTissue, Dr. Tseng served as Chair Professor at Bascom Palmer Eye Institute, consistently ranked among the world's top ophthalmology programs.
Dr. Tseng pioneered limbal stem cell transplantation and developed the revolutionary CRYOTEK cryopreservation process that preserves the natural therapeutic properties of amniotic membrane for clinical applications. With more than 380 peer-reviewed clinical and scientific papers, his research focus for over 35 years has been identifying the active biological components of human placental tissues and developing products to deliver their therapeutic properties. His groundbreaking work with cryopreserved amniotic membrane has revolutionized the management of ocular surface diseases, establishing new standards of care that minimize scarring and inflammation while promoting regenerative healing. This research directly led to the development of AmnioGraft, PROKERA, and CAM360, which have become essential tools for ophthalmologists worldwide and expanded into other medical fields through Amniox Medical. The clinical impact of Dr. Tseng's innovations is evident in the widespread adoption of his techniques and products across multiple healthcare sectors.
As Chief Scientific Officer, Dr. Tseng continues to drive research and development efforts to discover additional therapeutic applications of human birth tissues in regenerative healing for ocular surface disease and beyond. His vision has systematically expanded the use of cryopreserved amniotic membrane technology into surgical, chronic wound, and musculoskeletal applications through strategic company development. Dr. Tseng remains actively engaged in both clinical practice and research, maintaining his original mission to solve unmet patient needs through scientifically rigorous approaches to regenerative medicine. His leadership in the field continues to set the standard for evidence-based tissue therapy, with ongoing research focused on further understanding the biological mechanisms behind placental tissue healing properties. Dr. Tseng's enduring commitment to improving patient outcomes through innovation ensures his lasting influence on the future of regenerative medicine across multiple medical specialties worldwide.
